On the other hand, antagonizing FGF23 or inhibiting FGFR4 may block the pro-hypertrophic effects of excess FGF23, especially relevant in conditions like chronic kidney disease (CKD) and HHD [107]. Here, FGFR4 is linked to chronic kidney disease.